Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects [Phase 1]

View source ↗

Summary

A Phase 1 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of JX2105 in healthy Chinese subjects. P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• JX2105

Snippet

Sponsor: Zhejiang Jingxin Pharmaceutical Co., Ltd. | Conditions: Parkinson's Disease | Phase 1 | Status: ENROLLING_BY_INVITATION